Journal
CANCER INVESTIGATION
Volume 34, Issue 10, Pages 489-495Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357907.2016.1233424
Keywords
Glioma; temozolomide; deferiprone
Categories
Funding
- Joseph and Esther Gani Foundation
Ask authors/readers for more resources
Glioblastoma is the most malignant primary brain tumor with a median survival of 15months. Temozolomide (TMZ) is the standard of care for these patients. Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas. In the present study, we found that combination treatment in glioma cells with TMZ and DFP significantly reduced cell viability, produced cell cycle arrest at G2/M phase, and enhanced apoptosis. TMZ and DFP might be a potent new combination treatment for glioblastoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available